公开(公告)号：US20200323828A1

公开(公告)日：2020-10-15

申请号：US16635704

申请日：2018-08-03

Applicant: Oryzon Genomics, S.A.

Inventor： Tamara MAES ,  David ROTLLANT POZO ,  Christian GRIÑÁN FERRE ,  Mercè PALLÀS LLIBERIA ,  Roser NADAL ALEMANY ,  Antonio ARMARIO GARCÍA

IPC: A61K31/4245 ,  A61P25/18

Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

公开(公告)号：US20240277673A1

公开(公告)日：2024-08-22

申请号：US18451897

申请日：2023-08-18

Applicant: Oryzon Genomics, S.A.

Inventor： Tamara MAES ,  David ROTLLANT POZO ,  Christian GRIÑÁN FERRE ,  Mercè PALLÀSLLIBERIA ,  Roser NADAL ALEMANY ,  Antonio ARMARIO GARCÍA

IPC: A61K31/4245 ,  A61K9/00 ,  A61P25/18

CPC classification number: A61K31/4245 ,  A61P25/18 ,  A61K9/0053

Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.